News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AI hyperscalers have no plans to slow down spending in 2027.
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
ZS' Q4 earnings and revenues top estimates as rising platform adoption, AI demand and broad geographic growth drive 25% revenue growth and stronger ARR.
TWLO's 69% YTD rally is backed by accelerating growth, record free cash flow, raised guidance and rising demand for AI communications infrastructure.
The market is up in 2026 for the fourth consecutive year.
Yen surge puts treasury, Japan equity & yen ETFs in focus, but what is next for investors?
Snowflake's recent second-quarter results have analysts upgrading their price targets on the stock, citing its “killer AI ability” as the catalyst.
SIMO's 186.1% surge reflects strength in NAND controllers, expanding customer ties, product innovation and growth across AI, cloud and autos.
Assurant's embedded protection businesses, technology investments and strong cash generation support recurring growth and higher 2026 earnings expectations.
Should EME be a buy as record RPOs, strong construction demand and a raised 2026 outlook boost its growth prospects?
CBRL, GLBE and TXO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 4, 2026.
Carnival is caught in a perfect storm. Carnival’s stock hit a 52-week low on Tuesday, as the debt-logged cruise line navigates higher oil prices, a hantavirus scare for the cruise industry, and a geopolitical environment that’s keeping more travelers close to home.
Palo Alto (PANW) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SPCX briefly reclaimed a $2 trillion market cap as Starlink growth, launch dominance and AI ambitions fueled investor optimism despite execution risks.
MPC's 138.6% YTD surge is backed by strong refining execution, high-return projects and robust cash flow, though cyclical risks remain.
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Here is how Citigroup (C) and Federal Agricultural Mortgage (AGM) have performed compared to their sector so far this year.
Here is how Analog Devices (ADI) and ASM International NV (ASMIY) have performed compared to their sector so far this year.
PECO, NRIM, NDSN and LRCX raise dividends as geopolitical tensions fuel oil prices, inflation fears and market volatility.
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Old Dominion (ODFL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RDW expands its space and defense portfolio as backlog grows, but continued losses and contract execution risks cloud its outlook.
The average brokerage recommendation (ABR) for Newmont (NEM) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
According to the average brokerage recommendation (ABR), one should invest in Quanta Services (PWR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Based on the average brokerage recommendation (ABR), Archer Aviation (ACHR) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Jim Cramer called it both offensive and defensive, but the two halves of the Hugging Face deal are not equally interesting, and the one that actually moves the stock is the one Jensen Huang left out of his press tour talking points.
Fervo's been down sharply since its IPO, but that may be changing now.
Strategy’s return to Bitcoin buying after a 10-week pause comes as the cryptocurrency’s sharp rebound improves the outlook for its massive holdings and raises fresh questions about what comes next for MSTR stock.